CC
APLT

Checkpoint Capital’s Applied Therapeutics APLT Stock Holding History

Checkpoint Capital’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-227,470
Closed -$1.06M – 17
2024
Q2 		$1.06M Buy
227,470
+7,470
+3% +$35.3K 0.64% 14
2024
Q1 		$1.5M Buy
+220,000
New +$988K 1% 15

Other funds holding APLT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Checkpoint Capital's APLT Position: Q3 2024 in Review

Checkpoint Capital sold out of Applied Therapeutics (APLT) in Q3 2024, closing a stake of 227,470 shares — an estimated $1.06M sold.

Checkpoint Capital first reported a position in APLT in Q1 2024 and held it in 2 quarters. The position peaked at $1.5M in Q1 2024. 126 funds tracked by Wall St. Rank hold APLT as of Q3 2024.

  • Checkpoint Capital reported no remaining Applied Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Checkpoint Capital sold 227,470 Applied Therapeutics shares in Q3 2024, an estimated $1.06M.
  • Checkpoint Capital first reported a position in Applied Therapeutics in Q1 2024 and held it in 2 quarters.
  • Checkpoint Capital's Applied Therapeutics position peaked at $1.5M in Q1 2024.
  • 126 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2024.

Based on Checkpoint Capital's 13F filing for Q3 2024, filed 14 Nov 2024.